The value of bispecific antibodies in relapsed and refractory DLBCL

Research output: Contribution to journalReview articlepeer-review


Diffuse large B-cell lymphoma (DLBCL) may be cured with anti-CD20 based chemoimmunotherapy in the majority of cases, however, relapsed/refractory disease occurs in 30–40% patients, and despite significant recent therapeutic advances, continues to represent an unmet clinical need. Bispecific antibodies represent a novel class of therapy currently in development for relapsed/refractory B-cell lymphoma. This review discusses the background clinical need, mechanism of action, and clinical data including efficacy and toxicity for bispecific antibodies in DLBCL, focusing on the most advanced class in development; CD20 targeting T-cell engaging antibodies. Emerging possibilities for future use of bispecific antibodies is also discussed, including novel and cytotoxic combination regimens in relapsed and first-line settings.

Original languageEnglish
Pages (from-to)720-735
Number of pages16
JournalLeukemia and Lymphoma
Issue number6
Early online date7 Mar 2024
Publication statusPublished - 2024


Dive into the research topics of 'The value of bispecific antibodies in relapsed and refractory DLBCL'. Together they form a unique fingerprint.

Cite this